Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07224529 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of May 1, 2026 to Jun 1, 2026 · Site details revisedv5 Show 2 more changesShow less
    • Start date changed from estimate of May 1, 2026 to Jun 1, 2026
    • Site details revised
  2. Start date: Apr 1, 2026 to May 1, 2026v4
  3. Start date: Mar 1, 2026 to Apr 1, 2026v3
  4. Start date: Feb 1, 2026 to Mar 1, 2026v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD. You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.
Trial Details
NCT Number NCT07224529
Lead Sponsor University of Alabama at Birmingham
Collaborators: Harrow Inc
Conditions Meibomian Gland Dysfunction (MGD)
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov